Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 12 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Net sales exceeded the forecast because some active pharmaceutical ingredients for biosimilars and other products were delivered ahead of schedule from the following fiscal year. However, supply volumes fell below expectations due to losses on the disposal of inventories, causing operating income to fall below the lower end of the forecast range. The products delivered ahead of schedule were not subject to supply price revisions or manufacturing cost reductions, so their contribution to profit was limited.
Impairment loss on investment securities: ¥15.797 million; loss on cancellation of lease contracts: ¥21.774 million
| Item | Details |
|---|---|
| Net Sales | 6,000～6,500 → ¥6,589 million（+9.8%） |
| Operating profit | △100～100 → ¥-138 million（△38～－） |
| Ordinary income | Not disclosed → ¥-374 million |
| Profit attributable to owners of the parent | Not disclosed → ¥-413 million |
| Net income per share | Not disclosed → -8.48 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 February 2026 |
| Previous-period results | Net sales ¥5,082 million, operating income ¥27 million, ordinary income ¥5 million, net income attributable to owners of the parent negative ¥21 million, and earnings per share negative ¥0.52 |
| Reason for the revision | Net sales exceeded the forecast because some active pharmaceutical ingredients for biosimilars and other products were delivered ahead of schedule from the following fiscal year. However, supply volumes fell below expectations due to losses on the disposal of inventories, causing operating income to fall below the lower end of the forecast range. The products delivered ahead of schedule were not subject to supply price revisions or manufacturing cost reductions, so their contribution to profit was limited. |
| Details and amount of extraordinary loss | Impairment loss on investment securities: ¥15.797 million; loss on cancellation of lease contracts: ¥21.774 million |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Demand for active pharmaceutical ingredients for biosimilars and other products remained strong, and some products scheduled for delivery in the following fiscal year were delivered ahead of schedule, causing net sales to exceed the forecast. However, supply volumes fell below expectations because of losses on the disposal of inventories of certain active pharmaceutical ingredients and other products, causing operating income to fall below the lower end of the forecast range. In addition, the products delivered ahead of schedule were not subject to price revisions or manufacturing cost reductions, so their contribution to profit was limited.